On Tuesday, December 8, the interim results of the final phase of the clinical trial of the Oxford University and AstraZeneca neo-crown vaccine were made public through the medical journal Lancet, the first of a number of neo-crown vaccines to have Phase 3 clinical trial results published.
According to the report, which involved 11,636 volunteers from Brazil and the United Kingdom, the Oxford-AstraZeneca New Canopy vaccine achieved 70% effectiveness, with 62% effectiveness in volunteers who received two standard full-dose doses and 90% effectiveness observed in volunteers who received a half-dose followed by a full-dose dose. This is the first time a full peer-reviewed report has been published,” wrote the Lancet in its journal. Regarding the safety of the vaccine, the Lancet noted that based on the health reports of all 23,754 volunteers, it was “safe,” with only one person “experiencing serious adverse reactions that may be related to the injection. Another person had an adverse reaction after being given a placebo, and a third volunteer who had an adverse reaction belonged to an unknown injection group. All three have recovered or are getting better, according to the vaccine, and are still participating in the trial. Notably, a Brazilian volunteer died of neo-crown syndrome at the end of October, but Oxford has since announced that the safety of the clinical trial was not in question, and the local trial is continuing. The BBC previously reported that the deceased volunteer had understandably not been given the neoconvaccine.
Andrew Pollar, head of the Oxford Vaccine Group, said that the publication of the third-order trial results in the Lancet showed the willingness of the vaccine development team to share information transparently, noting that there is no direct competition between vaccines at this stage, because if you want to contain a pandemic in six months’ time, you can’t rely on just one vaccine, and if there is competition and confrontation, it can only be “between humans and viruses.
On the same day as the Lancet’s report, the United Kingdom was the first Western country to begin vaccinating its population with the new canopy vaccine, a joint venture between Pfizer of the United States and BioNTech of Germany. Previously, AstraZeneca’s New Crown vaccine development process was controversial and questionable because the 90% effectiveness of the vaccine was due to a coincidence of operational errors, while volunteers who were vaccinated according to a previously predetermined method only produced an average of 62% effectiveness. In addition, a third-order clinical trial report published by the Lancet on December 8 showed that none of the Oxford AstraZeneca volunteers who achieved 90% efficacy were over 55 years old.
The vaccine team said it has submitted additional information to the Lancet peer review to demonstrate that the vaccine’s effectiveness is not related to age, but acknowledged that further research is needed. AstraZeneca said that the decision on which vaccination approach to take would need to be made by the regulatory review board. Simon Clark, associate professor of cellular microbiology at the University of Reading, argues that the regulatory authority may be in a dilemma because, according to the report, although the vaccine that AstraZeneca Oxford incidentally found to be more effective was more effective in reducing asymptomatic transmission, the number of volunteers was relatively small and did not cover people over the age of 55.
Recent Comments